Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11920136 Transglutaminase-mediated conjugation

Patent 11920136 was granted and assigned to Tallac Therapeutics on March, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Current Assignee

Tallac Therapeutics

Date Filed

February 26, 2021

Date of Patent

March 5, 2024

Patent Applicant

Tallac Therapeutics

Patent Application Number

17187579

Patent Citations

‌

US Patent 9803016 Anti-CD47 antibodies and methods of use

‌

US Patent 9815898 Antibody molecules to PD-1 and uses thereof

‌

US Patent 11203611 Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use

‌

US Patent 9828434 Human monoclonal anti-PD-L1 antibodies and methods of use

‌

US Patent 7612181 Dual variable domain immunoglobulin and uses thereof

‌

US Patent 9381208 Structure and use of 5′ phosphate oligonucleotides

‌

US Patent 9650427 Modulators of antiviral signaling pathways and therapeutic uses thereof

‌

US Patent 9663575 CD47 antibodies and methods of use thereof

‌

US Patent 9738680 5′ triphosphate oligonucleotide with blunt end and uses thereof

Patent Inventor Names

Son Lam

Bang Janet Sim

Edward HyungSuk Ha

Jaume Pons

Curt W. Bradshaw

Hong I. Wan

Sukumar Sakamuri

Tracy Chia-Chien Kuo

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11920136

Patent Primary Examiner

CPC Code

•••

Find more entities like US Patent 11920136 Transglutaminase-mediated conjugation

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API

By using this site, you agree to our Terms of Service.